Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 55: 1056-1057, 2009. First published April 24, 2009; 10.1373/clinchem.2009.127084
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2009.127084v1
55/6/1056    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Avanzas, P.
Right arrow Articles by Kaski, J. C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Avanzas, P.
Right arrow Articles by Kaski, J. C.
(Clinical Chemistry. 2009;55:1056-1057.)
© 2009 American Association for Clinical Chemistry, Inc.

Editorials

Neopterin and Cardiovascular Disease: Growing Evidence for a Role in Patient Risk Stratification

Pablo Avanzas1,a, Ramón Arroyo-Espliguero2 and Juan Carlos Kaski3

1 Area del Corazón, Hospital Universitario Central de Asturias, Oviedo, Spain; 2 Cardiology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain; 3 Division of Cardiac and Vascular Sciences, St George’s University of London, London, UK.

aAddress correspondence to this author at: Área del Corazón, Hospital Universitario Central de Asturias., C/Julián Clavería S/N, 33006 Oviedo, Spain. Fax +34-985-27-46-88; e-mail avanzas@secardiologia.es.

The first 20% of the full text of this article appears below.

Compelling evidence has emerged in recent years regarding the implications of inflammation in the pathogenesis of atherosclerosis and its complications (1). The growing appreciation of the role of inflammation in atherogenesis, atheromatous plaque growth, and plaque disruption has triggered interest as to whether circulating inflammatory biomarkers may help to identify subjects at risk of future cardiovascular events. Of all currently available biomarkers, high-sensitivity C-reactive protein (hsCRP)1 appears to have the best profile as an independent predictor of increased coronary risk (2). Despite being a nonspecific acute-phase reactant, hsCRP has been shown in large epidemiological and clinical studies to be an independent predictor of cardiovascular events (3), i.e., myocardial infarction, stroke, and death in patients with angina (4) and apparently healthy subjects. Because hsCRP is not a specific marker of vascular inflammation, however, the search for highly sensitive and specific markers of risk continues unabated.

Evidence from our group (5)(6)(7)(8) and others (9)(10) in recent years indicates that neopterin, an immune modulator produced by activated macrophages, . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Association for Clinical Chemistry.